Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series

被引：11

作者：

Talotta R. ^{[1
]}

Atzeni F. ^{[2
]}

Batticciotto A. ^{[1
]}

Ditto M.C. ^{[1
]}

Gerardi M.C. ^{[1
]}

Sarzi-Puttini P. ^{[1
]}

机构：

[1] Department of Rheumatology, ASST Fatebenefratelli-Sacco, via GB Grassi n. 74, Milan

[2] Rheumatology Unit, University of Messina, via Consolare Valeria 1, Messina

来源：

Journal of Medical Case Reports | / 12卷 / 1期

关键词：

Rheumatic nodulosis; Rheumatoid arthritis; Tocilizumab;

D O I：

10.1186/s13256-018-1687-y

中图分类号：

学科分类号：

摘要：

Background: Tocilizumab is a monoclonal antibody directed against the interleukin-6 receptor, which is approved for the treatment of moderate-to-severe rheumatoid arthritis. Authors have found that it prevents lung and subcutaneous nodulosis in patients with rheumatoid arthritis but, to the best of our knowledge, there are no data concerning the acceleration of subcutaneous nodulosis during tocilizumab therapy. Case presentation: We report for the first time a small case series of five patients with rheumatoid arthritis: a 46-year-old white woman, a 70-year-old white woman, a 63-year-old white woman, a 69-year-old white man, and a 72-year-old white woman (mean age 64 ± 10.6 years); they experienced worsening subcutaneous nodulosis during treatment with intravenously administered tocilizumab. Four of the five patients were positive for rheumatoid factor and five for anti-citrullinated peptide antibodies. All of the patients had previously been treated with various conventional and biological drugs; at the time of our observation, three were taking methotrexate, two hydroxychloroquine, and four were taking prednisone. Tocilizumab 8 mg/kg was administered intravenously every 4 weeks for a mean of 43.4 ± 32.4 months, and led to good disease control in three cases. All of the patients had a history of subcutaneous nodulosis, which considerably worsened during tocilizumab treatment, with the development of new nodules on their fingers, elbows, or in the inframammary fold, tending to ulcerate. The management of this medical event included discontinuation of methotrexate, the administration of steroids, the addition of hydroxychloroquine or colchicine, the use of antibiotics, and surgery. However, neither pharmacological nor surgical treatment was completely effective, as the nodules tended to recur and increased in number and size. Conclusions: To the best of our knowledge, this is the first report describing accelerated subcutaneous nodulosis in a small case series of patients with rheumatoid arthritis treated with tocilizumab. © 2018 The Author(s).

引用

共 20 条

[1]

Andres M., Vela P., Romera C., Marked improvement of lung rheumatoid nodules after treatment with tocilizumab, Rheumatology (Oxford), 51, 6, pp. 1132-1134, (2012)

[2]

Al Attia H.M., Abushawish M., Treatment with tocilizumab leads to the disappearance of olecranon rheumatoid nodules, Int J Dermatol, 51, 2, pp. 197-198, (2012)

[3]

Tilstra J.S., Rheumatoid Nodules L.D.W., Dermatol Clin, 33, 3, pp. 361-371, (2015)

[4]

Mattey D.L., Dawes P.T., Fisher J., Brownfield A., Thomson W., Hajeer A.H., Et al., Nodular disease in rheumatoid arthritis: Association with cigarette smoking and HLA-DRB1/TNF gene interaction, J Rheumatol, 29, 11, pp. 2313-2318, (2002)

[5]

Hessian P.A., Highton J., Kean A., Sun C.K., Chin M., Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma, Arthritis Rheum, 48, 2, pp. 334-338, (2003)

[6]

Stamp L.K., Easson A., Lehnigk U., Highton J., Hessian P.A., Different T., Cell subsets in the nodule and synovial membrane: Absence of interleukin-17A in rheumatoid nodules, Arthritis Rheum, 58, 6, pp. 1601-1608, (2008)

[7]

Peters A., Pitcher L.A., Sullivan J.M., Mitsdoerffer M., Acton S.E., Franz B., Et al., Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation, Immunity, 35, 6, pp. 986-996, (2011)

[8]

Pesce B., Soto L., Sabugo F., Wurmann P., Cuchacovich M., Lopez M.N., Sotelo P.H., Et al., Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients, Clin Exp Immunol, 171, 3, pp. 237-242, (2013)

[9]

Thiolat A., Semerano L., Pers Y.M., Biton J., Lemeiter D., Portales P., Et al., Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis, Arthritis Rheumatol, 66, 2, pp. 273-283, (2014)

[10]

Guggino G., Giardina A.R., Raimondo S., Giardina G., Sireci G., Dieli F., Et al., Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion, Clin Exp Rheumatol, 32, 1, pp. 77-81, (2014)

← 1 2 →